Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been assigned an average rating of “Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $43.17.
A number of equities research analysts have recently commented on the stock. BTIG Research upped their price objective on shares of Spyre Therapeutics from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Wells Fargo & Company boosted their price objective on Spyre Therapeutics from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, May 13th. Robert W. Baird assumed coverage on Spyre Therapeutics in a research note on Thursday, May 2nd. They set an “outperform” rating and a $50.00 target price for the company. Finally, Stifel Nicolaus boosted their price target on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th.
Get Our Latest Analysis on SYRE
Spyre Therapeutics Stock Up 0.9 %
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, equities research analysts expect that Spyre Therapeutics will post -3.82 EPS for the current year.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
See Also
- Five stocks we like better than Spyre Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Sales Breakout Sends This Semiconductor Stock to Record High
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Surprise Buying Opportunity on This Dividend Aristocrat
- With Risk Tolerance, One Size Does Not Fit All
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.